April 30, 2018 / 8:14 PM / 3 months ago

BRIEF-Novartis Says Phase III Data For Brolucizumab Demonstrate Reliability Of 12-Week Treatment Interval

April 30 (Reuters) - Novartis AG:

* PHASE III DATA FOR BROLUCIZUMAB DEMONSTRATE RELIABILITY OF 12-WEEK TREATMENT INTERVAL

* NOVARTIS- PATIENTS FOR BROLUCIZUMAB 12-WEEK TREATMENT IN PHASE III HAWK AND HARRIER TRIALS HAD 87% AND 83% PROBABILITY OF CONTINUING 12-WEEK INTERVAL THROUGH WEEK 48

* BROLUCIZUMAB SAFETY WAS COMPARABLE TO AFLIBERCEPT WITH OVERALL INCIDENCE OF ADVERSE EVENTS BALANCED ACROSS ALL TREATMENT GROUPS IN BOTH STUDIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below